Genus

GNS.LApproved

Basingstoke, United KingdomFounded 1994genusplc.com

Genus is a UK-based, publicly traded biotechnology company focused on the agricultural sector, specializing in the genetic improvement of livestock. Its core mission is to pioneer animal genetic improvement to help nourish the world by delivering superior breeding animals and technical services to farmers. The company operates through two primary divisions: PIC (porcine) and ABS (bovine), leveraging proprietary genetics, biotechnology, and data analytics. Its strategic direction involves continuous R&D in genetics, genomics, and reproductive technologies to enhance traits like feed efficiency, disease resistance, and sustainability.

Market Cap

$1.7B

Founded

1994

Employees

2000-2500

Focus

Biotech

GNS.L · Stock Price

USD 2555.00321.00 (-11.16%)

Historical price data

AI Company Overview

Technology Platform

Integrated platform combining proprietary quantitative genetics, genomic selection using DNA markers, advanced reproductive technologies (AI, embryo transfer), and biotechnology R&D (including gene editing) to deliver superior genetic traits in pigs and cattle.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
GO-203-2C + Bortezomib	Multiple Myeloma	Phase 1
GO-203-2c	Solid Tumors	Phase 1

Funding History

IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEANDAFeb 18, 2025

CIPROFLOXACIN HYDROCHLORIDEANDANov 5, 2024

CHLORPROMAZINE HYDROCHLORIDEANDAJun 2, 2021

Opportunities

Genus is poised for growth through the global expansion of advanced genetic services, particularly in emerging markets like Asia and Latin America.

The potential commercial launch of its gene-edited, PRRS-resistant pigs represents a transformative, high-margin product opportunity.

Furthermore, increasing focus on sustainable food production creates demand for genetics that improve efficiency and reduce environmental impact.

Risk Factors

Key risks include regulatory uncertainty surrounding gene-edited animals, particularly in major markets like Europe and China.

The business is exposed to cyclical downturns in agricultural commodity prices, which can reduce farmer investment.

Disease outbreaks (e.g., African Swine Fever) and geopolitical trade tensions can also disrupt operations and demand in key regions.

Competitive Landscape

Genus competes with global animal genetics leaders like Topigs Norsvin (pigs) and CRV/Semex (cattle), as well as regional players. Its differentiation lies in its scale, deep R&D investment, integrated supply chain for pigs, and strong technical service model. Its pioneering work in gene editing for disease resistance could create a significant future competitive advantage if successfully commercialized.

Publications

Patents

Pipeline

FDA Approvals